Development of a Robust Reporter-based T cell Activation Assay for Therapeutic Biologics in Immunotherapy
Poster Oct 09, 2015
Zhi-jie Jey Cheng, Pete Stecha, Jim Hartnett, Frank Fan, and Mei Cong
Jurkat T-cells stably expressing luciferase reporter driven by IL2 promoter or NFAT-RE, are used as effector cells. Tumor cell lines endogenously expressing cancer antigen are used as antigen presenting cells (APC). By co-cultivating the two cell lines in the presence of CD3 bispecific antibody, TCR/CD3 is activated in Jurkat effector cells. Luciferase activity is up regulated through IL-2 promoter or NFAT-RE activation.
Biologics-based medicines is a rapidly growing field and a promising solution to address many unmet medical needs. Biopharmaceutical developers are actively looking for more efficient and robust production platforms to reduce timelines and overall development costs. Gibco™ Expi™ Expression Systems are complete platforms that can speed up biologics development.READ MORE